The Psychometric Properties and Clinical Use of the Turkish Version of the Functional Assessment of Cancer Therapy–Lung FACT-L Scale

Yıl 2019, , 139 - 144, 01.09.2019

Burcu Başarık Aydoğan Tuncay Göksel Ahmet Emin Erbaycu Aysen Öz Pınar Çelik Kader Kıyar Gürsul Ebru Çakır Edis Osman Hatipoğlu Bedriye Atay Yayla Sevin Başer Hakan Baydur Erhan Eser

https://doi.org/10.30621/jbachs.2019.652

Öz

Objectives:psychometric properties of the Turkish version of the Functional Assessment of Cancer Therapy-Lung FACT-L scale and the sensitivity to changes in clinical indicators. Patients and Methods:This study was conducted within the framework of a national multicentre project. Patients with either stage IIIB or IV primary lung cancer diagnosed after April 2010were included in thisstudy. A classical confirmatory approach was used for both the reliability and validity analyses. Internal consistency was tested using Cronbach’s α value, and the validity analysis was performed using construct validity and clinical validity. Results:276 92.3% patients were male and the average age was 60.8 ± 9.4 years. The most frequently observed histological type was squamous cell carcinoma 36.8% , and 61.5% of these stage IV tumours. Cronbachs α values for the subscales ranged from 0.60 to 0.84. The majority of the FACT-L subscales revealed inter-scale correlation coefficients greater than 0.35. All sub-dimensions, except that of the social/family well-being scale, are able to significantly discriminate between stages IIIB and IV. Significantly lower scale scores were detected in patients with stage IV than stage IIIB. The comparative fit index was 0.917, and the root mean square error of approximation was 0.091. Dyspnoea, haemoptysis, chest pain, weight loss, anorexia, localised pain, and fever symptoms had a significant correlation with the FACT-L, trial outcome index, and lung cancer subscale. Conclusion:Turkish version of the psychometric properties of the original FACT-L scale is regarded as a valid and reliable tool and can be used safely in a clinical context when managing patients with lung cancer in Turkey

Anahtar Kelimeler

Lung cancer, quality of life, FACT-L

Kaynakça

• Globocan 2012. http://globocan.iarc.fr/ia/World/atlas.html Accessed: 09 Jan 2014.
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98. [CrossRef]
• Ochs J, Grous JJ, Warner KL. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U. S. expanded access program (EAP). J Clin Oncol 2004;22:060.
• Aaronson NK, Ahmedzai S, Bullinger M, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376. [CrossRef]
• Wan C, Zhang C, Cai L, et al. Psychometric properties of the Chinese version of the FACT-L for measuring quality of life in patients with lung cancer. Lung Cancer 2007;56:415–421. [CrossRef]
• Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy -- Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199–220. [CrossRef]
• Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005;28:192–211. [CrossRef]
• Yoo H, Suh C, Kim S, Eremenco S, Kim H, Kim S. Korean translation and validation of the Functional Assessment of Cancer Therapy-Lung (FACT-L) version 4. Qual Life Res 2006;15:161–166. [CrossRef]
• Saitoh E, Yokomizo Y, Chang CH, Eremenco S, Kaneko H, Kobayashi K. Cross-cultural validation of the Japanese Version of the Lung Cancer Subscale on the Functional Assessment of Cancer Therapy-Lung. J. Nippon Med Sch 2007;74:402–408. [CrossRef]
• Dapueto JJ, Francolino C, Servente L, et al. Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish version 4 in South America: classic psychometric and item response theory analyses. Health Qual Life Outcomes 2003;1:32. [CrossRef]
• Cella D, Eton D, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285–295. [CrossRef]
• Franceschini J, Jardim JR, Fernandes ALG, Jamnik S, Santoro IL. Reliability of the Brazilian version of the Functional Assessment of Cancer Therapy‐Lung (FACT‐L) and the FACT‐Lung Symptom Index (FLSI) Clinics (Sao Paulo) 2010;65:1247–1251. [CrossRef]
• Butt Z, Webster K, Eisenstein AR, et al. Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapy-Lung Scale. Hematol Oncol Clin N Am,2005;19:389–420. [CrossRef]
• Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993;11:570–579. [CrossRef]
• SSII Scientific Software International Inc. LISREL for Windows 8. Lincolnwood, IL, USA; 2003.
• Global Adult Tobacco Survey Turkey 2012. Ankara: Republic of Turkey Ministry of Health, Publication No:948; 2014.
• Znaor A, van den Hurk C, Primic-Zakelj M, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. Eur J Cancer 2013;49:1683– 1691. [CrossRef]
• Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–9. [CrossRef]
• Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005–1;23:2946–2954. [CrossRef]
• Browning KK, Ferketich AK, Otterson GA, Reynolds NR, Wewers ME. A psychometric analysis of quality of life tools in lung cancer patients who smoke. Lung Cancer 2009;66:134–139. [CrossRef]
• Saitoh E, Yokomizo Y, Chang C-H, Eremenco S, Kaneko H, Kobayashi K. Cross-cultural validation of the Japanese version of the lung cancer subscale on the Functional Assessment of Cancer Therapy-Lung. J Nippon Med Sch 2007;74:402–408. [CrossRef]
• Smith EL, Hann DM, Ahles TA, et al. Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage 2001;21:323–329. [CrossRef]